A Phase 1 interventional study of Brimonidine Tartrate 0.025% and Vehicle in Glaucoma and Ocular Hypertension, sponsored by Eye Therapies, LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-12-25.
Sponsored by Eye Therapies, LLC · Phase 1, Interventional, and Treatment
The purpose of this study is to determine the intraocular Pressure (IOP) lowering response and evaluate the safety of brimonidine tartrate 0.025% ophthalmic solution in adult subjects with open angle glaucoma or ocular hypertension.
1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.
This study's enrollment of 15 is below the median of 65 across 1,272 interventional studies indexed under Glaucoma.
Browse Glaucoma studies →Eye Therapies, LLC is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Brimonidine Tartrate 0.025% · Drug: Vehicle
Drug: Brimonidine Tartrate 0.025% · Drug: Vehicle
1 drop in each eye daily four times a day for 14 days
1 drop in each eye daily four times a day for 14 days
IOP
Time frame: 14 days
Number of Participants with Adverse Events as a Measure of Safety
Time frame: For up to 8 weeks
This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eye Therapies, LLC